Gastrointestinal Stromal Tumors
Conditions
Interventions
Test group:Radiotherapy combined with oral ripretinib
Sponsors
The First Affiliated Hospital of Chongqing Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Voluntarily participate and sign an informed consent form in writing; 2. Age range from 18 to 75 years old, regardless of gender; 3. Patients histologically diagnosed with GIST; 4. The subject's ECOG physical condition score is 0-2; 5. Disease progression or intolerance to first-line, second-line, and third-line treatments; 6. Based on imaging evidence, the lesion was assessed by MDT as unresectable and suitable for local radiotherapy; 7. No severe abnormalities in the hematologic, cardiac, pulmonary, hepatic, renal functions, or immune deficiency; 8. Expected survival of more than 3 months.
Exclusion criteria
Exclusion criteria: 1. Patients with resectable GIST; 2. Patients who have previously received radiotherapy at the intended site, or have a high tumor activity and poor tolerance to radiotherapy in adjacent organs, and are deemed unsuitable for radiotherapy after MDT discussion; 3. Patients with other serious illnesses such as severe infections, severe bone marrow suppression, and mental disorders , etc., deemed ineligible for enrollment by the researchers;; 4. Pregnant or lactating women.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Progression-Free Survival; | — |
Secondary
| Measure | Time frame |
|---|---|
| Overall Survival;Objective Response Rate;Disease Control Rate; | — |
Countries
China
Contacts
Public ContactJun Zhang
The First Affiliated Hospital of Chongqing Medical University
Outcome results
None listed